Pharmafile Logo
Pharmafocus logo
Advanced Search

Genmab

Showing 15 posts of 31 posts found.

shutterstock_273326141

AbbVie and Genmab sign drug development and commercialisation deal worth up to $4bn

June 11, 2020
Research and Development AbbVie, Genmab, partnership, pharma

AbbVie has joined forces with Genmab to develop and commercialise three of the latter’s early-stage Genmab drug products – epcoritamab …

News
anthony_mancini

Genmab announces newly-created Chief Financial Officer appointment

March 16, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Genmab, pharma

Genmab has announced the establishment of the new position of Chief Operating Officer at the company, and has furthermore named …

Appointment
darzalex-product-shot---100mg-vial-2-hr

Genmab’s Darzalex secures CHMP recommendation in Europe for front-line multiple myeloma

December 13, 2019
Medical Communications, Sales and Marketing CHMP, Genmab, darzalex, pharma

The Committee for Medicinal Products for Human Use (CHMP), an advisory panel for the European Medicines Agency, has given its …

News
darzalex-product-shot---100mg-vial-2-hr

European Commission approves Genmab’s Darzalex combo in newly diagnosed multiple myeloma

November 20, 2019
Research and Development, Sales and Marketing Europe, Genmab, darzalex, pharma

Genmab’s Darzalex (daratumumab) has secured approval from the European Commission and is now authorised in Europe for the treatment of …

News
david_eatwell

Genmab’s Executive VP and CFO to retire in 2020

October 31, 2019
Research and Development Genmab, appointment, pharma

David Eatwell, Executive Vice President and Chief Financial Officer at Genmab, has announced his intention to step down from the …

News
darzalex-product-shot---100mg-vial-2-hr

FDA approves Genmab’s Darzalex combo in newly diagnosed multiple myeloma

September 27, 2019
Medical Communications, Sales and Marketing FDA, Genmab, darzalex, pharma

Genmab’s CD38 inhibitor Darzalex (daratumumab) has been awarded marketing authorisation from the FDA in combination with bortezomib, thalidomide and dexamethasone …

News
novartis_outside_1

Novartis’ ofatumumab outclasses Sanofi’s Aubagio at Phase 3 in relapsing multiple sclerosis

September 3, 2019
Manufacturing and Production, Research and Development Arzerra, Genmab, Novartis, multiple sclerosis, pharma

New data from two Phase 3 studies have indicated that Novartis’ ofatumumab outperformed Sanofi Genzyme’s Aubagio (teriflunomide) in the treatment …

News
shutterstock_159488225

Genmab & Novartis’ ofatumumab tops Sanofi’s Aubagio in relapsing multiple sclerosis

August 30, 2019
Medical Communications, Research and Development Genmab, Novartis, multiple sclerosis, ofatumumab, pharma

Genmab and Novartis have revealed positive new data from two Phase 3 studies of its monthly subcutaneous formulation of ofatumumab …

News
jj

J&J terminates PD-(L)1 combo studies of cancer therapy Darzalex

May 29, 2018
Manufacturing and Production, Research and Development Cancer, Genmab, J&J, JJ, Johnson & Johnson, Roche, darzalex, multiple myeloma, tecentriq

Johnson & Johnson is to terminate its studies investigating Genmab’s CD38-targeting, human IgG1κ monoclonal antibody Darzalex (daratumumab) in combination with …

News

Genmab and Janssen’s Darzalex combo scores FDA approval in multiple myeloma

May 8, 2018
Manufacturing and Production, Sales and Marketing FDA, Genmab, Janssen, US, darzalex, multiple myeloma, pharma

Genmab and Janssen have revealed that their combination of Darzalex (daratumumab) with bortezomib (Velcade), melphalan, and prednisone (VMP) has received …

News

J&J’s Darzalex cuts risk of disease progression and death by 50%, new study shows

December 13, 2017
Research and Development Genmab, J&J, JJ, Janssen, Johnson & Johnson, darzalex, multiple myeloma, pharma

Johnson and Johnson has revealed data which demonstrates that Darzalex (daratumumab), when combined with a regimen of bortezomib, melphalan and …

News
jj_2johnson_and_johnson

J&J and Genmab’s drug races to second line treatment approval

November 22, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Genmab, Janssen, Johnson & Johnson, darzalex, multiple myeloma

Janssen, a part of Johnson & Johnson, and Genmab have announced that their multiple myeloma drug Darzalex (daratumumab) has been …

News
gilead-sciences

Gilead to work with Genmab on HIV targeting technology

August 12, 2016
Medical Communications, Research and Development, Sales and Marketing Genmab, Gilead, HIV, duobody

Genmab has announced that it has entered into a collaboration deal with Gilead Sciences to use the DuoBody technology platform …

News
janssen_latest_logo_on_sign_closer

Darzalex receives breakthrough designation in multiple myeloma from FDA

July 26, 2016
Manufacturing and Production, Research and Development FDA, Genmab, Janssen, darzalex, multiple myeloma

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Darzalex (daratumumab) in combination with standard of …

News
cancer

Genmab’s CLL drug gets negative opinion from EMA committee

June 24, 2016
Medical Communications, Research and Development, Sales and Marketing Arzerra, CHMP, CLL, EMA, Genmab, blood cancer

Genmab A/S (Nasdaq Copenhagen: GEN) said its drug Arzerra (ofatumumab) received a negative opinion by the Committee for Medicinal Products …

News

Latest content

Austrian state secretary to speak at FlyPharma Europe 2023

September 29, 2023

Karuna Therapeutics submits NDA to FDA for schizophrenia treatment

September 29, 2023

Kura Oncology shares preclinical data for NSCLC treatment

September 29, 2023

BactiVac funds development of bacterial vaccines to prevent infections against antimicrobial resistance

September 28, 2023

Avalyn Pharma raises $175m in Series C financing for inhalation therapies

September 28, 2023